75 phenotypes from 7 alleles in 12 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Gt(ROSA)26Sortm1(CAG-Kcnj11*,-GFP)Nich/Gt(ROSA)26Sor+ Tg(Ins2-cre)23Herr/0 involves: C57BL/6 * CBA/J	abnormal circulating glucagon level	J:146650
	abnormal circulating glucose level	J:146650
	abnormal pancreas morphology	J:146650
	abnormal pancreatic alpha cell morphology	J:146650
	abnormal pancreatic beta cell physiology	J:146650
	abnormal pancreatic islet morphology	J:146650
	decreased circulating glucagon level	J:146650
	decreased circulating insulin level	J:146650
	decreased insulin secretion	J:146650
	decreased pancreas weight	J:146650
	decreased pancreatic alpha cell number	J:146650
	decreased pancreatic beta cell number	J:146650
	decreased pancreatic islet number	J:146650
	hyperglycemia	J:146650
	increased circulating glucagon level	J:146650
	slow postnatal weight gain	J:146650
	small pancreatic islets	J:146650
Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor+ Tg(Nes-cre)1Kln/0 involves: 129S4/SvJae * C57BL/6 * SJL	abnormal action potential	J:162008
	abnormal channel response	J:162008
	abnormal nervous system electrophysiology	J:162008
	decreased body weight	J:162008
	decreased grip strength	J:162008
	hyperactivity	J:162008
	impaired balance	J:162008
	impaired coordination	J:162008
	muscle weakness	J:162008
	perinatal lethality, incomplete penetrance	J:162008
Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor+ Tg(Ins2-cre)23Herr/0 involves: 129S4/SvJae * C57BL/6	abnormal pancreatic alpha cell morphology	J:144715
	abnormal pancreatic beta cell morphology	J:144715
	abnormal pancreatic beta cell physiology	J:144715
	abnormal pancreatic islet morphology	J:144715
	decreased body weight	J:144715
	decreased circulating insulin level	J:144715
	decreased insulin secretion	J:144715
	decreased pancreatic beta cell number	J:144715
	increased circulating glucagon level	J:144715
	increased circulating glucose level	J:144715
	increased pancreatic alpha cell number	J:144715
	polyuria	J:144715
Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor+ Tg(Pdx1-cre/Esr1*)#Dam/0 involves: 129S4/SvJae * C57BL/6 * CBA	hyperglycemia	J:210493
Kcnj11tm1b(EUCOMM)Wtsi/Kcnj11tm1b(EUCOMM)Wtsi C57BL/6N-Kcnj11tm1b(EUCOMM)Wtsi/H	abnormal ear morphology	J:211773
	decreased fasting circulating glucose level	J:211773
	decreased hemoglobin content	J:211773
	impaired glucose tolerance	J:211773
Kcnj11tm1Sse/Kcnj11+ Tg(Ins1-Kcnj11*)#Nich/? involves: 129P2/OlaHsd * C57BL/6 * CBA	abnormal pancreatic beta cell physiology	J:94610
	decreased insulin secretion	J:94610
	impaired glucose tolerance	J:94610
	improved glucose tolerance	J:94610
	increased circulating glucose level	J:94610
	increased circulating insulin level	J:94610
	increased insulin secretion	J:94610
Kcnj11tm1Sse/Kcnj11tm1Sse B6.129P2-Kcnj11tm1Sse	abnormal action potential	J:106396
	abnormal food intake	J:69163, J:157001
	abnormal glucose homeostasis	J:69163
	abnormal locomotor activation	J:157001
	abnormal nerve fiber response	J:69163
	decreased abdominal fat pad weight	J:157001
	decreased aerobic running capacity	J:157001
	decreased glucagon secretion	J:69163
	decreased subcutaneous adipose tissue amount	J:157001
	decreased susceptibility to diet-induced obesity	J:157001
	hypoglycemia	J:69163
	increased circulating atrial natriuretic factor	J:106396
	increased energy expenditure	J:157001
	increased mean systemic arterial blood pressure	J:106396
	increased oxygen consumption	J:157001
	normal pigmentation phenotype	J:157001
	slow postnatal weight gain	J:157001
Kcnj11tm1Sse/Kcnj11tm1Sse involves: 129P2/OlaHsd	abnormal muscle relaxation	J:105244
	abnormal nerve fiber response	J:69832
	abnormal nerve fiber response intensity	J:69832
	convulsive seizures	J:69832
	decreased circulating insulin level	J:49755
	impaired glucose tolerance	J:49755
	impaired skeletal muscle contractility	J:105244, J:140833
	increased insulin sensitivity	J:49755
	increased muscle fatigability	J:140833
	increased susceptibility to induced morbidity/mortality	J:69832
	myoclonus	J:69832
	tonic-clonic seizures	J:69832
Kcnj11tm1Sse/Kcnj11tm1Sse involves: 129P2/OlaHsd * C57BL/6	abnormal emotion/affect behavior	J:112822
	abnormal locomotor activation	J:112822
	abnormal motor capabilities/coordination/movement	J:112822
	abnormal spatial reference memory	J:112822
	decreased anxiety-related response	J:112822
	decreased exploration in new environment	J:112822
	decreased vertical activity	J:112822
	impaired coordination	J:112822
	increased anxiety-related response	J:112822
Kcnj11tm1Sse/Kcnj11tm1Sse Tg(Ins1-Kcnj11*)#Nich/? involves: 129P2/OlaHsd * C57BL/6 * CBA	decreased insulin secretion	J:94610
	normal homeostasis/metabolism phenotype	J:94610
	impaired glucose tolerance	J:94610
	increased circulating glucose level	J:94610
Kcnj11Y12stop/Kcnj11Y12stop involves: BALB/c * C3H/HeH	decreased glucagon secretion	J:122088
	increased insulin secretion	J:122088
Tg(Ins1-Kcnj11*)#Nich/? B6.Cg-Tg(Ins1-Kcnj11*)#Nich	increased insulin secretion	J:94610
Tg(Myh6-Kcnj11*)1Wco/0 involves: C57BL/6 * FVB/N	abnormal impulse conducting system conduction	J:116284
	abnormal myocardial fiber currents	J:116284
	abnormal myocardial fiber physiology	J:116284
	decreased QRS amplitude	J:116284
	premature death	J:116284